ストックスクリーナーアプリを入手
2.405
6.50%
0.165
前日終値:
$2.24
開ける：
$2.27
24時間の取引高:
253.09K
Relative Volume:
0.18
時価総額：
$169.74M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.9007
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
+21.71%
1か月 パフォーマンス:
+6.97%
6か月 パフォーマンス:
-25.45%
1年 パフォーマンス:
-58.15%
1日の値動き範囲:
$2.245
$2.40
1週間の範囲:
$2.00
$2.94
52週間の値動き範囲:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.385 | 172.23M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.05 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.35 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.94 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.04 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.38 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
Why is C4 Therapeutics Inc. stock going downDay Trading 5x Gain Picks - mustnews.co.kr
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Why C4 Therapeutics Inc. stock attracts strong analyst attentionStock Forecast Tools for Retail Traders - Newser
What earnings revisions data tells us about C4 Therapeutics Inc.Free Growth Based Investment Plan Guidance - Newser
Real time breakdown of C4 Therapeutics Inc. stock performanceDaily Pick Forecast with Entry Zones - Newser
Is C4 Therapeutics Inc. stock ready for a breakoutTechnical Trade Plan with Entry Checklist - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsWeekly Gain Forecast with Momentum Indicators - Newser
New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Smart Swing Picks with Confirmed Signals - Newser
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 2025 Q2 Earnings Widened Losses Amid Mixed Price Performance - AInvest
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M - simplywall.st
C4 Therapeutics Reports Q2 2025 Financial Results - TipRanks
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Q2 2025 Financial Results: Revenue Down to $6.5M, Cash Position at $223M - AInvest
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
C4 Therapeutics, Inc. SEC 10-Q Report - TradingView
C4 Therapeutics reports Q2 2025 results, cemsidomide Phase 1 data accepted at IMS. - AInvest
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What drives C4 Therapeutics Inc. stock priceBuild wealth faster with disciplined trading - Jammu Links News
Is it the right time to buy C4 Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
What makes C4 Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
What is C4 Therapeutics Inc. company’s growth strategyMaximize returns with strategic trading plans - Jammu Links News
When is C4 Therapeutics Inc. stock expected to show significant growthGet timely alerts on top market movers - Jammu Links News
What is the dividend policy of C4 Therapeutics Inc. stockUnlock daily trading alerts for profits - Jammu Links News
Is C4 Therapeutics Inc. stock overvalued or undervaluedSuperior stock growth - Jammu Links News
Why is C4 Therapeutics Inc. stock attracting strong analyst attentionUnmatched market performance - Jammu Links News
Is C4 Therapeutics Inc. a growth stock or a value stockFree Capital Allocation Plans - Jammu Links News
What are C4 Therapeutics Inc. company’s key revenue driversGet alerts on high-potential market moves - Jammu Links News
What is the risk reward ratio of investing in C4 Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
What are the latest earnings results for C4 Therapeutics Inc.Invest confidently with professional market insights - Jammu Links News
What are analysts’ price targets for C4 Therapeutics Inc. in the next 12 monthsInvest confidently with market-leading analysis - Jammu Links News
Here's What Analysts Are Forecasting For C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its First-Quarter Results - 富途牛牛
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Protara Therapeutics Grants $45K Worth of Stock Options and RSUs to Strategic New Employees - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
0.26%
大文字化:
|
ボリューム (24 時間):